Featured
IGC Announces Financial Results for Quarter Ended September 30, 2018
IGC Announces Financial Results for Quarter Ended September 30, 2018
IGC Files Provisional Patent to Protect IP for CBD-Infused Energy Drink
IGC Files Provisional Patent to Protect IP for CBD-Infused Energy Drink
IGC to Enter the Hemp/CBD-Infused Energy Drink Space
IGC to Enter the Hemp/CBD-Infused Energy Drink Space
India Globalization Capital Raises $1 Million in Direct Equity Investment to Support Hyalolex Commercialization
India Globalization Capital Raises $1 Million in Direct Equity Investment to Support Hyalolex Commercialization
IGC to Enter California Market with Hyalolex
IGC to Enter California Market with Hyalolex
IGC Announces Results of its 2018 Annual Stockholders Meeting
IGC Announces Results of its 2018 Annual Stockholders Meeting
IGC Announces Financial Results for Quarter Ended June 30, 2018
IGC Announces Financial Results for Quarter Ended June 30, 2018
IGC Announces “Drops of Clarity” Marketing Initiatives for Hyalolex™
IGC Announces “Drops of Clarity” Marketing Initiatives for Hyalolex™
IGC to Hold Annual Meeting of Stockholders on August 6, 2018
IGC to Hold Annual Meeting of Stockholders on August 6, 2018
IGC Announces Financial Results for Fiscal Year Ended March 31, 2018
IGC Announces Financial Results for Fiscal Year Ended March 31, 2018
IGC Files Patent for Hyalolex Formulation
IGC Files Patent for Hyalolex Formulation
IGC Radica Patente para la Fórmula Hyalolex
IGC Radica Patente para la Fórmula Hyalolex
IGC Partners to Launch Hyalolex in Puerto Rico
IGC Partners to Launch Hyalolex in Puerto Rico
IGC Appoints Carrolee Barlow, MD, PhD as Advisor to Help Develop Cannabis Related Products for Treating Various End Points of Parkinson’s Disease and Movement Disorders (PDMD)
IGC Appoints Carrolee Barlow, MD, PhD as Advisor to Help Develop Cannabis Related Products for Treating Various End Points of Parkinson’s Disease and Movement Disorders (PDMD)
IGC Partners with Parkinson’s Institute and Clinical Center to Develop Cannabis Related Products for Treating Various End Points of Parkinson’s Disease and Movement Disorders (PDMD)
IGC Partners with Parkinson’s Institute and Clinical Center to Develop Cannabis Related Products for Treating Various End Points of Parkinson’s Disease and Movement Disorders (PDMD)
IGC Announces Third Quarter Financial Results Advances Hyalolex to Commercialization Stage
IGC Announces Third Quarter Financial Results Advances Hyalolex to Commercialization Stage
IGC's CEO to Speak at CEO Healthcare Symposium in NY on February 12 & 13
IGC's CEO to Speak at CEO Healthcare Symposium in NY on February 12 & 13
IGC Reports Promising Spatial Memory Results in Alzheimer’s Study
IGC Reports Promising Spatial Memory Results in Alzheimer’s Study
IGC to Use Blockchain to Address Issues Specific to the Medical Cannabis Industry
IGC to Use Blockchain to Address Issues Specific to the Medical Cannabis Industry
IGC Announces Adjournment of Annual Meeting Voting for Proposals Three and Four to Dec 29, 2017
IGC Announces Adjournment of Annual Meeting Voting for Proposals Three and Four to Dec 29, 2017
IGC Provides Update on Hyalolex for Alzheimer’s Commercialization Strategy
IGC Provides Update on Hyalolex for Alzheimer’s Commercialization Strategy
IGC Launches New Corporate Websites Highlighting Canna-Pharmaceutical Compound Portfolio
IGC Launches New Corporate Websites Highlighting Canna-Pharmaceutical Compound Portfolio
IGC Announces Adjournment of Annual Meeting Voting for Proposals Three and Four to Dec 15, 2017
IGC Announces Adjournment of Annual Meeting Voting for Proposals Three and Four to Dec 15, 2017
IGC Reports Second Quarter 2018 Financial Results and Operational Highlights
IGC Reports Second Quarter 2018 Financial Results and Operational Highlights
IGC Announces Results of Annual Shareholders Meeting
IGC Announces Results of Annual Shareholders Meeting
IGC Regains NYSE American Listing Compliance
IGC Regains NYSE American Listing Compliance
IGC to Distribute its Formulations in Germany in Early 2018
IGC to Distribute its Formulations in Germany in Early 2018
IGC-AD1 Targeting Alzheimer’s Disease to be commercialized in early 2018 Through Medical Dispensaries
IGC-AD1 Targeting Alzheimer’s Disease to be commercialized in early 2018 Through Medical Dispensaries
NYSE American Extends India Globalization Capital Compliance Plan Period
NYSE American Extends India Globalization Capital Compliance Plan Period
IGC Prepares a Liquid Delivery Formulation of IGC-AD1 for Alzheimer’s Based on Novel In Vitro Data
IGC Prepares a Liquid Delivery Formulation of IGC-AD1 for Alzheimer’s Based on Novel In Vitro Data